Business Wire
01 Oct 2026, 06:30 UTC · 1w ago
Impact · against what's priced in
Pfizer's positive Phase 2 data for tilrekimig provides a tangible catalyst for its dermatology pipeline. The successful achievement of EASI-75 endpoints supports a transition to Phase 3 trials, offering a potential new growth lever in the atopic dermatitis market.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Pfizer's Phase 2 study of tilrekimig in adults with moderate-to-severe atopic dermatitis met its primary endpoint, showing a statistically significant increase in EASI-75 achievement at Week 16 across all doses.
Newpresented today via BUSINESS WIRE
So whatPositive Phase 2 data typically triggers a transition to Phase 3 trials, which will impact R&D spend over the next 12-24 months.
More positive than 94% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The statistically significant increase in EASI-75 achievement across all doses at Week 16 validates the efficacy of tilrekimig, paving the way for Phase 3 development.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 90% of ticker scores this week
Positive Phase 2 study results for tilrekimig in treating atopic dermatitis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
+2.4%
Price agrees with the score
$29.21 vs $28.52 close before publication (Sep 30) · not market-adjusted
PFE chart →
